Contribution of EGFR and ErbB-3 Heterodimerization to the EGFR Mutation-Induced Gefitinib- and Erlotinib-Resistance in Non-Small-Cell Lung Carcinoma Treatments.

Contribution of EGFR and ErbB-3 Heterodimerization to the EGFR Mutation-Induced Gefitinib- and Erlotinib-Resistance in Non-Small-Cell Lung Carcinoma Treatments.

EGFR mutation-induced drug resistance has become a major threat to the treatment of non-small-cell lung carcinoma. Essentially, the resistance mechanism involves modifications of the intracellular signaling pathways. In our work, we separately investigated the EGFR and ErbB-3 heterodimerization, reg...

Volledige beschrijving

Bibliografische gegevens
Hoofdauteurs: Debby D Wang, Lichun Ma, Maria P Wong, Victor H F Lee, Hong Yan
Formaat: Artikel
Taal:English
Gepubliceerd in: Public Library of Science (PLoS) 2015-01-01
Reeks:PLoS ONE
Online toegang:http://europepmc.org/articles/PMC4439022?pdf=render

Internet

http://europepmc.org/articles/PMC4439022?pdf=render

Gelijkaardige items